Top

Published in:

01-07-2010 | Epidemiology

Lack of association between CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis of 22,090 cases and 28,498 controls

Authors: Chen Mao, Xi-Wen Wang, Ben-Fu He, Li-Xin Qiu, Ru-Yan Liao, Rong-Cheng Luo, Qing Chen

Published in: Breast Cancer Research and Treatment | Issue 1/2010

Abstract

Epidemiological studies have evaluated the association between CYP17 MspA1 polymorphism and breast cancer risk. However, the results remain conflicting rather than conclusive. To derive a more precise estimation of the relationship, we performed this meta-analysis. Systematic searches of the PubMed and Medline databases were performed. A total of 35 studies including 22,090 cases and 28,498 controls were identified. Genotype distributions of CYP17 in the controls of all studies were in agreement with Hardy–Weinberg equilibrium (HWE) except for three studies. When all 35 studies were pooled into the meta-analysis, there was no evidence for significant association between CYP17 MspA1 polymorphism and breast cancer risk (for A1/A2 vs. A1/A1: OR = 1.00, 95% CI = 0.96–1.04; for A2/A2 vs. A1/A1: OR = 1.03, 95% CI = 0.97–1.08; for dominant model: OR = 1.01, 95% CI = 0.97–1.05; for recessive model: OR = 1.03, 95% CI = 0.98–1.08). In the subgroup analyses by ethnicity, menopausal status and source of controls, no significant associations were found in all genetic models. When sensitivity analyses were performed by excluding HWE-violating studies, all the results were not materially altered. In summary, the meta-analysis strongly suggests that CYP17 MspA1 polymorphism is not associated with increased breast cancer risk.

Brentano ST, Picado-Leonard J, Mellon SH, Moore CC, Miller WL (1990) Tissue-specific, cyclic adenosine 3′,5′-monophosphate-induced, and phorbol ester-repressed transcription from the human P450c17 promoter in mouse cells. Mol Endocrinol 4(12):1972–1979CrossRefPubMed

Cavalieri EL, Stack DE, Devanesan PD, Todorovic R, Dwivedy I, Higginbotham S, Johansson SL, Patil KD, Gross ML, Gooden JK, Ramanathan R, Cerny RL, Rogan EG (1997) Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc Natl Acad Sci USA 94(20):10937–10942CrossRefPubMed

Service RF (1998) New role for estrogen in cancer? Science 279(5357):1631–1633CrossRefPubMed

Fan YS, Sasi R, Lee C, Winter JS, Waterman MR, Lin CC (1992) Localization of the human CYP17 gene (cytochrome P450(17 alpha)) to 10q24.3 by fluorescence in situ hybridization and simultaneous chromosome banding. Genomics 14(4):1110–1111CrossRefPubMed

Carey AH, Waterworth D, Patel K, White D, Little J, Novelli P, Franks S, Williamson R (1994) Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 3(10):1873–1876CrossRefPubMed

Kadonaga JT, Jones KA, Tjian R (1986) Promoter-specific activation of RNA polymerase II transcription by Sp1. Trends Biochem Sci 11(1):20–23CrossRef

Feigelson HS, Coetzee GA, Kolonel LN, Ross RK, Henderson BE (1997) A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res 57(6):1063–1065PubMed

Dunning AM, Healey CS, Pharoah PD, Foster NA, Lipscombe JM, Redman KL, Easton DF, Day NE, Ponder BA (1998) No association between a polymorphism in the steroid metabolism gene CYP17 and risk of breast cancer. Br J Cancer 77(11):2045–2047PubMed

Helzlsouer KJ, Huang HY, Strickland PT, Hoffman S, Alberg AJ, Comstock GW, Bell DA (1998) Association between CYP17 polymorphisms and the development of breast cancer. Cancer Epidemiol Biomarkers Prev 7(10):945–949PubMed

10.

Weston A, Pan CF, Bleiweiss IJ, Ksieski HB, Roy N, Maloney N, Wolff MS (1998) CYP17 genotype and breast cancer risk. Cancer Epidemiol Biomarkers Prev 7(10):941–944PubMed

11.

Bergman-Jungeström M, Gentile M, Lundin AC, Wingren S (1999) Association between CYP17 gene polymorphism and risk of breast cancer in young women. Int J Cancer 84(4):350–353CrossRefPubMed

12.

Haiman CA, Hankinson SE, Spiegelman D, Colditz GA, Willett WC, Speizer FE, Kelsey KT, Hunter DJ (1999) The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res 59(5):1015–1020PubMed

13.

Huang CS, Chern HD, Chang KJ, Cheng CW, Hsu SM, Shen CY (1999) Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res 59(19):4870–4875PubMed

14.

Nedelcheva Kristensen V, Haraldsen EK, Anderson KB, Lønning PE, Erikstein B, Kåresen R, Gabrielsen OS, Børresen-Dale AL (1999) CYP17 and breast cancer risk: the polymorphism in the 5′ flanking area of the gene does not influence binding to Sp-1. Cancer Res 59(12):2825–2828PubMed

15.

Young IE, Kurian KM, Annink C, Kunkler IH, Anderson VA, Cohen BB, Hooper ML, Wyllie AH, Steel CM (1999) A polymorphism in the CYP17 gene is associated with male breast cancer. Br J Cancer 81(1):141–143CrossRefPubMed

16.

Hamajima N, Iwata H, Obata Y, Matsuo K, Mizutani M, Iwase T, Miura S, Okuma K, Ohashi K, Tajima K (2000) No association of the 5′ promoter region polymorphism of CYP17 with breast cancer risk in Japan. Jpn J Cancer Res 91(9):880–885PubMed

17.

Kuligina ES, Togo AV, Suspitsin EN, Grigoriev MY, Pozharisskiy KM, Chagunava OL, Berstein LM, Theillet C, Hanson KP, Imyanitov EN (2000) CYP17 polymorphism in the groups of distinct breast cancer susceptibility: comparison of patients with the bilateral disease vs. monolateral breast cancer patients vs. middle-aged female controls vs. elderly tumor-free women. Cancer Lett 156(1):45–50CrossRefPubMed

18.

Mitrunen K, Jourenkova N, Kataja V, Eskelinen M, Kosma VM, Benhamou S, Vainio H, Uusitupa M, Hirvonen A (2000) Steroid metabolism gene CYP17 polymorphism and the development of breast cancer. Cancer Epidemiol Biomarkers Prev 9(12):1343–1348PubMed

19.

Miyoshi Y, Iwao K, Ikeda N, Egawa C, Noguchi S (2000) Genetic polymorphism in CYP17 and breast cancer risk in Japanese women. Eur J Cancer 36(18):2375–2379CrossRefPubMed

20.

Spurdle AB, Hopper JL, Dite GS, Chen X, Cui J, McCredie MR, Giles GG, Southey MC, Venter DJ, Easton DF, Chenevix-Trench G (2000) CYP17 promoter polymorphism and breast cancer in Australian women under age forty years. J Natl Cancer Inst 92(20):1674–1681CrossRefPubMed

21.

Feigelson HS, McKean-Cowdin R, Coetzee GA, Stram DO, Kolonel LN, Henderson BE (2001) Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two important candidates. Cancer Res 61(2):785–789PubMed

22.

McCann SE, Moysich KB, Freudenheim JL, Ambrosone CB, Shields PG (2002) The risk of breast cancer associated with dietary lignans differs by CYP17 genotype in women. J Nutr 132(10):3036–3041PubMed

23.

Ambrosone CB, Moysich KB, Furberg H, Freudenheim JL, Bowman ED, Ahmed S, Graham S, Vena JE, Shields PG (2003) CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors. Breast Cancer Res 5(2):R45–R51CrossRefPubMed

24.

Gudmundsdottir K, Thorlacius S, Jonasson JG, Sigfusson BF, Tryggvadottir L, Eyfjord JE (2003) CYP17 promoter polymorphism and breast cancer risk in males and females in relation to BRCA2 status. Br J Cancer 88(6):933–936CrossRefPubMed

25.

Tan W, Qi J, Xing DY, Miao XP, Pan KF, Zhang L, Lin DX (2003) Relation between single nucleotide polymorphism in estrogen-metabolizing genes COMT, CYP17 and breast cancer risk among Chinese women. Zhonghua Zhong Liu Za Zhi 25(5):453–456PubMed

26.

Wu AH, Seow A, Arakawa K, Van Den Berg D, Lee HP, Yu MC (2003) HSD17B1 and CYP17 polymorphisms and breast cancer risk among Chinese women in Singapore. Int J Cancer 104(4):450–457CrossRefPubMed

27.

Ahsan H, Whittemore AS, Chen Y, Senie RT, Hamilton SP, Wang Q, Gurvich I, Santella RM (2005) Variants in estrogen-biosynthesis genes CYP17 and CYP19 and breast cancer risk: a family-based genetic association study. Breast Cancer Res 7(1):R71–R81CrossRefPubMed

28.

Hefler LA, Tempfer CB, Grimm C, Lebrecht A, Ulbrich E, Heinze G, Leodolter S, Schneeberger C, Mueller MW, Muendlein A, Koelbl H (2004) Estrogen-metabolizing gene polymorphisms in the assessment of breast carcinoma risk and fibroadenoma risk in Caucasian women. Cancer 101(2):264–269CrossRefPubMed

29.

Chacko P, Rajan B, Mathew BS, Joseph T, Pillai MR (2004) CYP17 and SULT1A1 gene polymorphisms in Indian breast cancer. Breast Cancer 11(4):380–388CrossRefPubMed

30.

Chang JH, Gertig DM, Chen X, Dite GS, Jenkins MA, Milne RL, Southey MC, McCredie MR, Giles GG, Chenevix-Trench G, Hopper JL, Spurdle AB (2005) CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors: Australian Breast Cancer Family Study. Breast Cancer Res 7(4):R513–R521CrossRefPubMed

31.

Einarsdóttir K, Rylander-Rudqvist T, Humphreys K, Ahlberg S, Jonasdottir G, Weiderpass E, Chia KS, Ingelman-Sundberg M, Persson I, Liu J, Hall P, Wedrén S (2005) CYP17 gene polymorphism in relation to breast cancer risk: a case-control study. Breast Cancer Res 7(6):R890–R896CrossRefPubMed

32.

Han DF, Zhou X, Hu MB, Xie W, Mao ZF, Chen DE, Liu F, Zheng F (2005) Polymorphisms of estrogen-metabolizing genes and breast cancer risk: a multigenic study. Chin Med J (Engl) 118(18):1507–1516

33.

Hopper JL, Hayes VM, Spurdle AB, Chenevix-Trench G, Jenkins MA, Milne RL, Dite GS, Tesoriero AA, McCredie MR, Giles GG, Southey MC (2005) A protein-truncating mutation in CYP17A1 in three sisters with early-onset breast cancer. Hum Mutat 26(4):298–302CrossRefPubMed

34.

Shin MH, Lee KM, Yang JH, Nam SJ, Kim JW, Yoo KY, Park SK, Noh DY, Ahn SH, Kim B, Kang D (2005) Genetic polymorphism of CYP17 and breast cancer risk in Korean women. Exp Mol Med 37(1):11–17PubMed

35.

Verla-Tebit E, Wang-Gohrke S, Chang-Claude J (2005) CYP17 5′-UTR MspA1 polymorphism and the risk of premenopausal breast cancer in a German population-based case-control study. Breast Cancer Res 7(4):R455–R464CrossRefPubMed

36.

Hu MB, Xie W, Xiong B, Han DF, Li Y, Feng MH, Zhou YF (2006) Study on the relationship between polymorphisms of genes (CYP17, CYP19 and SULT1A1) and susceptibility to breast cancer in Chinese women. Zhonghua Liu Xing Bing Xue Za Zhi 27(4):351–355PubMed

37.

Piller R, Verla-Tebit E, Wang-Gohrke S, Linseisen J, Chang-Claude J (2006) CYP17 genotype modifies the association between lignan supply and premenopausal breast cancer risk in humans. J Nutr 136(6):1596–1603PubMed

38.

Chakraborty A, Murthy NS, Chintamani C, Bhatnagar D, Mohil RS, Sharma PC, Saxena S (2007) CYP17 gene polymorphism and its association with high-risk north Indian breast cancer patients. J Hum Genet 52(2):159–165CrossRefPubMed

39.

Setiawan VW, Schumacher FR, Haiman CA, Stram DO, Albanes D, Altshuler D, Berglund G, Buring J, Calle EE, Clavel-Chapelon F, Cox DG, Gaziano JM, Hankinson SE, Hayes RB, Henderson BE, Hirschhorn J, Hoover R, Hunter DJ, Kaaks R, Kolonel LN, Kraft P, Ma J, Le Marchand L, Linseisen J, Lund E, Navarro C, Overvad K, Palli D, Peeters PH, Pike MC, Riboli E, Stampfer MJ, Thun MJ, Travis R, Trichopoulos D, Yeager M, Ziegler RG, Spencer Feigelson H, Chanock SJ (2007) CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiol Biomarkers Prev 16(11):2237–2246CrossRefPubMed

40.

Chen Y, Gammon MD, Teitelbaum SL, Britton JA, Terry MB, Shantakumar S, Eng SM, Wang Q, Gurvich I, Neugut AI, Santella RM, Ahsan H (2008) Estrogen-biosynthesis gene CYP17 and its interactions with reproductive, hormonal and lifestyle factors in breast cancer risk: results from the Long Island Breast Cancer Study Project. Carcinogenesis 29(4):766–771CrossRefPubMed

41.

Sakoda LC, Blackston C, Doherty JA, Ray RM, Lin MG, Stalsberg H, Gao DL, Feng Z, Thomas DB, Chen C (2008) Polymorphisms in steroid hormone biosynthesis genes and risk of breast cancer and fibrocystic breast conditions in Chinese women. Cancer Epidemiol Biomarkers Prev 17(5):1066–1073CrossRefPubMed

42.

Torresan C, Oliveira MM, Torrezan GT, de Oliveira SF, Abuázar CS, Losi-Guembarovski R, Lima RS, Urban CA, Cavalli IJ, Ribeiro EM (2008) Genetic polymorphisms in oestrogen metabolic pathway and breast cancer: a positive association with combined CYP/GST genotypes. Clin Exp Med 8(2):65–71CrossRefPubMed

43.

Zhang L, Gu L, Qian B, Hao X, Zhang W, Wei Q, Chen K (2009) Association of genetic polymorphisms of ER-alpha and the estradiol-synthesizing enzyme genes CYP17 and CYP19 with breast cancer risk in Chinese women. Breast Cancer Res Treat 114(2):327–338CrossRefPubMed

44.

Antognelli C, Del Buono C, Ludovini V, Gori S, Talesa VN, Crinò L, Barberini F, Rulli A (2009) CYP17, GSTP1, PON1 and GLO1 gene polymorphisms as risk factors for breast cancer: an Italian case-control study. BMC Cancer 9:115CrossRefPubMed

45.

The MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk (2009) Postmenopausal estrogen monotherapy-associated breast cancer risk is modified by CYP17A1_-34_T>C polymorphism. Breast Cancer Res Treat. doi:10.1007/s10549-009-0490-2

46.

Samson M, Rama R, Swaminathan R, Sridevi V, Nancy KN, Rajkumar T (2009) CYP17 (T34C), CYP19 (Trp39Arg), and FGFR2 (C906T) polymorphisms and the risk of breast cancer in south Indian women. Asian Pac J Cancer Prev 10(1):111–114PubMed

47.

Sangrajrang S, Sato Y, Sakamoto H, Ohnami S, Laird NM, Khuhaprema T, Brennan P, Boffetta P, Yoshida T (2009) Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women. Int J Cancer 125(4):837–843CrossRefPubMed

48.

Ye Z, Parry JM (2002) The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis. Mutagenesis 17(2):119–126CrossRefPubMed

49.

Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10(1):101–129CrossRef

50.

Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22(4):719–748PubMed

51.

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188CrossRefPubMed

52.

Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634PubMed

Title: Lack of association between CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis of 22,090 cases and 28,498 controls
Authors: Chen Mao
Xi-Wen Wang
Ben-Fu He
Li-Xin Qiu
Ru-Yan Liao
Rong-Cheng Luo
Qing Chen
Publication date: 01-07-2010
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-009-0695-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

PALB2 mutations in male breast cancer: a population-based study in Central Italy

Dietary lignan intakes in relation to survival among women with breast cancer: the Western New York Exposures and Breast Cancer (WEB) Study

Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers

SULT1A1 R213H polymorphism and breast cancer risk: a meta-analysis based on 8,454 cases and 11,800 controls

Effect of BRCA1/2 mutation on short-term and long-term breast cancer survival: a systematic review and meta-analysis

HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment

Keynote webinar | Spotlight on antibody–drug conjugates in cancer